Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets
Cash	$ 16,143,080	$ 18,652,841
Accounts receivable, net of allowances of $88,310 and $99,278	3,409,048	2,861,014
Accounts receivable - related party	96,278	79,787
Royalty receivable	49,344	49,344
Inventory, net of allowance for obsolescence of $359,577 and $333,850	2,171,328	2,048,191
Prepaid and other assets	624,923	917,318
Total current assets	22,494,001	24,608,495
Long-term assets
Property and equipment, net	1,578,973	1,629,845
Right of use assets – operating leases	355,081	412,770
Intangible assets, net	4,617,947	4,727,970
Investment in equity securities	4,887,718	5,017,351
Total long-term assets	11,439,719	11,787,936
Total assets	33,933,720	36,396,431
Current liabilities
Accounts payable	929,374	438,154
Accounts payable – related parties	51,847	155,817
Accrued royalties and expenses	940,337	706,196
Accrued bonus and commissions	3,129,203	4,518,817
Operating lease liability - current	180,233	203,292
Total current liabilities	5,230,994	6,022,276
Long-term liabilities
Operating lease liability – long term	187,040	222,151
Total long-term liabilities	187,040	222,151
Total liabilities	5,418,034	6,244,427
Commitments and contingencies (Note 6)
Shareholders’ equity
Common Stock: $0.001 par value, 20,000,000 shares authorized; 7,810,395 issued and outstanding as of March 31, 2022 and 7,676,662 issued and outstanding as of December 31, 2021	7,810	7,677
Additional paid-in capital	47,438,466	45,867,768
Accumulated deficit	(18,415,012)	(15,235,044)
Total Sanara MedTech shareholders’ equity	29,031,264	30,640,401
Equity attributable to noncontrolling interest	(515,578)	(488,397)
Total shareholders’ equity	28,515,686	30,152,004
Total liabilities and shareholders’ equity	$ 33,933,720	$ 36,396,431